Continuous-flow API synthesis — the manufacturing revolution Indian pharma cannot ignore
Why batch chemistry will not be the dominant Indian API manufacturing mode in 2035 — and what disciplined operators are doing today to be ready.
The single biggest manufacturing-process shift coming to Indian pharmaceutical chemistry over the next decade is the move from purely batch synthesis to continuous and hybrid flow-batch processes. The technology is mature, the economics are increasingly favourable, the regulatory acceptance has progressed, and the global customers are starting to ask. Most Indian SMEs in regulated APIs have not yet meaningfully invested. The ones who do — quietly, carefully, on the right molecules — will have a significant operating advantage by the end of the decade. From Anand, this is how I am thinking about it.
Batch versus flow, briefly
Traditional batch chemistry runs reactions in large vessels — a charge is loaded, the reaction is run, the product is isolated, the vessel is cleaned, the next batch begins. Continuous-flow chemistry runs the same reactions through small-volume pipes and microreactors continuously — feed streams enter at one end, product exits at the other, with much tighter control over residence time, temperature and concentration.
The advantages for the right reactions are meaningful: faster reaction times, better selectivity, smaller plant footprint, dramatically improved safety for hazardous chemistries, and consistent quality batch-to-batch. The trade-offs are real: not every reaction works well in flow, capital cost per unit of capacity is higher initially, and the operating team needs different skills.
Why this matters for Indian regulated APIs
Three reasons. One — global regulatory bodies (FDA, EMA, PMDA) have all signaled clear acceptance and even encouragement of continuous manufacturing for APIs. The regulatory headwind that existed a decade ago is gone. Two — customer audits increasingly ask about continuous capability, especially for high-potency APIs and hazardous chemistries where batch operations carry residual risk. Three — Indian competitive position has historically rested on labour cost arbitrage in batch chemistry. That arbitrage is eroding. The next sustainable advantage is process know-how and capability — exactly where flow chemistry sits.
Where flow chemistry wins, and where it doesn't
Flow chemistry is genuinely better for: highly exothermic reactions, hazardous chemistries (azide, peroxide, ozonolysis, hydrogenations), photochemistry, very fast reactions, and any process where impurity profile depends critically on residence time control. It is not particularly better for: long reaction times (hours-to-days), heterogeneous solid-laden reactions, or simple reactions where batch is already optimal.
The practical answer for most Indian regulated-API manufacturers is hybrid. Convert the specific reaction steps in an existing multi-step synthesis where flow delivers meaningful gains; leave the rest batch. This kind of incremental hybridisation captures most of the upside without requiring a full plant rebuild.
What we are doing at Laksh, concretely
Two operating bets we are making over the next three years. One — pilot-scale flow chemistry capability for two specific reaction families in our current portfolio where the impurity-profile advantages are well-documented. The capital cost is modest at pilot scale; the learning curve is the actual cost. Two — selective conversion of one production-scale step in our iodine derivative synthesis to flow, where the existing batch process has known safety and selectivity constraints that flow chemistry resolves.
These are not headline-grabbing investments. They are quiet, customer-driven, and aimed at building the operating know-how that will be table stakes by 2030. The pattern matches our broader operating philosophy — invest ahead of the demand curve, build the capability, and let the customer relationships compound on the resulting differentiation.
What other Indian manufacturers should consider
Three pieces of advice for any Indian SME thinking about continuous manufacturing. One — start with one molecule and one reaction step, not a full plant conversion. The economics and the learning curve both favour small, targeted investments over capital-intensive bets. Two — partner with an Indian or international engineering firm that has actual flow-chemistry production deployments. The capability gap between simulation and operating reality is large. Three — train two or three of your senior chemists deeply on flow chemistry process design before you commission any equipment. The technology fails when the operating team doesn't fully understand it.
Where this goes by 2035
By the mid-2030s, my view is that the bulk of new regulated-API capacity built in India will be hybrid — flow where it wins, batch where it makes sense. The pure-batch Indian API plant will look the way pure-manual textile mills looked in 2000: still operating, but increasingly squeezed on cost, quality and customer perception by the next-generation alternative. The Indian manufacturers who started the transition in the 2020s will be the natural global supplier-of-choice for the molecules where flow advantage is decisive.
This is not a fad. It is a generational shift in manufacturing modality, similar in scale to the shift from semi-batch to fully continuous distillation in the petrochemical industry decades ago. India can either lead the shift in regulated APIs or follow it. From Laksh's vantage point in Anand, leading is the only answer that compounds.
Got a question on what you've just read — or a project that touches one of the categories above? Write directly to the office.
First-generation Indian industrialist. Founder and Managing Director of Laksh Finechem — a WHO-GMP, FDA and ISO-certified manufacturer of APIs, iodine derivatives and specialty chemicals.